𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells

✍ Scribed by Rosella Silvestrini; Nadia Zaffaroni; Raffaella Villa; Linda Orlandi; Aurora Costa

Publisher
John Wiley and Sons
Year
1992
Tongue
French
Weight
524 KB
Volume
52
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

The ability of lonidamine, an energolytic derivative of indazolecarboxylic acid, to modulate the cytotoxicity of cisplatin was investigated in human ovarian-cancer cell lines sensitive (A2780) or with experimentally induced resistance (A2780/cp8) to the alkylating agent. A 24-hr post-incubation with 300 pM lonidamine significantly potentiated the activity of a I-hr cisplatin treatment in both cell lines. In particular, the cisplatin ICso value was reduced 4-fold in the sensitive line and 5-fold in the resistant line. Flow cytometric analysis showed that, in the resistant cell line, lonidamine alone did not affect cell kinetics, but when given after cisplatin it was able to transform the temporary G, + M cell accumulation induced by the alkylating agent to a persistent block in S/G2 + M. In the A2780/cp8 cell line, lonidamine was also able to significantly enhance the accumulation of cisplatin-induced DNA interstrand cross-links.

Our results suggest that lonidamine can positively modulate the anti-tumor activity of cisplatin in ovarian cancer cells and also indicate that the drug is potentially useful in combination therapy including the alkylating agent for ovarian cancer patients.

📜 SIMILAR VOLUMES

Lonidamine as a modulator of taxol activ
Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis
✍ Linda Orlandi; Nadia Zaffaroni; Alessandra Bearzatto; Raffaella Villa; Cinzia De 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 188 KB 👁 2 views

The ability of lonidamine (LND), an energolytic derivative of indazole-carboxylic acid, to modulate the cytotoxicity of Taxol (TX) was investigated in the A2780 human ovarian cancer cell line. Different cytotoxicity results were obtained as a function of treatment schedule. Specifically, TX followed

Mechanism of interaction between cisplat
Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell lines
✍ Alissar Nehmé; Nicolas Albin; Marie Josée Caliaro; Sylvie Guichard; Suzanne Joza 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 857 KB

## Abstract Human ovarian carcinoma cells (2008 and its cisplatin‐resistant sub‐line 2008/C13\*) were sensitized to cisplatin by treatment with human recombinant gamma interferon (IFNγ). IFNγ produced no significant change in the uptake of CDDP. Exposure of 2008 and 2008/C13\* cells to IFNγ resulte

Quercetin enhances transforming growth f
Quercetin enhances transforming growth factor β1, secretion by human ovarian cancer cells
✍ Giovanni Scambia; Pierluigi Benedetti Panici; F. O. Ranelletti; G. Ferrandina; R 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 594 KB

## Abstract Our study demonstrates that quercetin (Q)‐induced growth‐inhibitory activity in ovarian cancer cells may be mediated by modulation of transforming growth factor β~1~ (TGFβ~1~) production. We used the OVCA 433 cell line which is very sensitive to the anti‐proliferative effect of Q and ex

Akt promotes cisplatin resistance in hum
Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function
✍ Michael Fraser; Tao Bai; Benjamin K. Tsang 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 736 KB

## Abstract Resistance to cisplatin‐based chemotherapy is a major cause of treatment failure in human ovarian cancer. Wild‐type __TP53__ status is often, but not always, associated with cisplatin sensitivity, suggesting that additional factors may be involved. Overexpression/activation of the phosp